Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
Collegium to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 04'th Mar 2025
STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conf
Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript
09:03pm, Thursday, 27'th Feb 2025
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Vikram Karnani - Presiden
Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
08:00pm, Thursday, 27'th Feb 2025
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
06:45pm, Thursday, 27'th Feb 2025
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.58 per share a year ago.
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
04:01pm, Thursday, 27'th Feb 2025
– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM ® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue o
Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:15am, Wednesday, 26'th Feb 2025
Evaluate the expected performance of Collegium Pharmaceutical (COLL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some o
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
08:00am, Thursday, 13'th Feb 2025
STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the mar
Collegium Provides 2025 Financial Guidance and Business Update
08:00am, Wednesday, 08'th Jan 2025
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
08:00am, Tuesday, 26'th Nov 2024
Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of J
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)
04:30pm, Thursday, 14'th Nov 2024
MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JO
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
10:45am, Wednesday, 13'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
09:35am, Friday, 08'th Nov 2024
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript
12:30am, Friday, 08'th Nov 2024
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interi
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
07:30pm, Thursday, 07'th Nov 2024
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates
06:37pm, Thursday, 07'th Nov 2024
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.
